MX2010008371A - Inhibidores de catepsina b. - Google Patents

Inhibidores de catepsina b.

Info

Publication number
MX2010008371A
MX2010008371A MX2010008371A MX2010008371A MX2010008371A MX 2010008371 A MX2010008371 A MX 2010008371A MX 2010008371 A MX2010008371 A MX 2010008371A MX 2010008371 A MX2010008371 A MX 2010008371A MX 2010008371 A MX2010008371 A MX 2010008371A
Authority
MX
Mexico
Prior art keywords
fibrosis
hcv
liver
disease
liver fibrosis
Prior art date
Application number
MX2010008371A
Other languages
English (en)
Spanish (es)
Inventor
Leslie Holsinger
Original Assignee
Virobay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virobay Inc filed Critical Virobay Inc
Publication of MX2010008371A publication Critical patent/MX2010008371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
MX2010008371A 2008-02-07 2009-02-05 Inhibidores de catepsina b. MX2010008371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2700708P 2008-02-07 2008-02-07
PCT/US2009/033229 WO2009100225A1 (en) 2008-02-07 2009-02-05 Inhibitors of cathepsin b

Publications (1)

Publication Number Publication Date
MX2010008371A true MX2010008371A (es) 2010-10-04

Family

ID=40939419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008371A MX2010008371A (es) 2008-02-07 2009-02-05 Inhibidores de catepsina b.

Country Status (9)

Country Link
US (1) US8211897B2 (enExample)
EP (1) EP2237793A4 (enExample)
JP (2) JP5718647B2 (enExample)
CN (1) CN101969973B (enExample)
BR (1) BRPI0907729A2 (enExample)
CA (1) CA2713108A1 (enExample)
EA (1) EA201001262A1 (enExample)
MX (1) MX2010008371A (enExample)
WO (1) WO2009100225A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2009005057A0 (en) 2007-05-10 2009-12-31 Array Biopharma Inc Novel peptide inhibitors of hepatitis c virus replication
KR20110005869A (ko) 2008-04-15 2011-01-19 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
CN103946213A (zh) * 2011-11-25 2014-07-23 霍夫曼-拉罗奇有限公司 作为组织蛋白酶抑制剂的新吡咯烷衍生物
US20140256698A1 (en) * 2013-03-11 2014-09-11 Virobay, Inc. Cathepsin inhibitors
AU2016378723B2 (en) 2015-12-22 2021-09-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
MX392422B (es) 2016-06-21 2025-03-24 Orion Ophthalmology LLC Derivados de prolinamida heterociclica
CN109661389A (zh) * 2016-08-23 2019-04-19 豪夫迈·罗氏有限公司 作为htra1抑制剂的新型二氟酮酰胺衍生物
US10834908B2 (en) * 2017-04-26 2020-11-17 InfiCure Bio AB Model animal for fibrosis
MA49458A (fr) 2017-06-21 2020-04-29 SHY Therapeutics LLC Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques
WO2019018451A2 (en) * 2017-07-17 2019-01-24 The Regents Of The University Of Colorado COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED PROXIMITY EFFECTS CAUSED BY RADIATION OR RADIATION THERAPY
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100287A3 (en) 1997-11-11 2003-04-28 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US6404397B1 (en) 1998-08-10 2002-06-11 Raytheon Company Compact all-weather electromagnetic imaging system
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
WO2001055123A1 (en) 2000-01-26 2001-08-02 Ono Pharmaceutical Co., Ltd. Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
AU2004274051A1 (en) 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
WO2006113942A2 (en) 2005-04-20 2006-10-26 Schering Corporation Method of inhibiting cathepsin activity
US20060276406A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
WO2006130554A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
WO2006130688A2 (en) 2005-06-02 2006-12-07 Schering Corporation Compounds for inhibiting cathepsin activity
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
US20080161254A1 (en) 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors

Also Published As

Publication number Publication date
EA201001262A1 (ru) 2011-04-29
JP2011511089A (ja) 2011-04-07
BRPI0907729A2 (pt) 2015-07-14
CN101969973B (zh) 2015-07-22
EP2237793A4 (en) 2013-07-31
JP5718647B2 (ja) 2015-05-13
CA2713108A1 (en) 2009-08-13
JP2015051985A (ja) 2015-03-19
WO2009100225A1 (en) 2009-08-13
US20090203629A1 (en) 2009-08-13
EP2237793A1 (en) 2010-10-13
CN101969973A (zh) 2011-02-09
US8211897B2 (en) 2012-07-03

Similar Documents

Publication Publication Date Title
MX2010008371A (es) Inhibidores de catepsina b.
MY151045A (en) Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
MA35608B1 (fr) 3,5-diamino-6-chloro-n-(n-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)-amino)éthoxy)phényl)butyl)carbamimidoyl)pyrazine-2-carboxamide
IL190084A (en) Amidated pyrimidinyl compounds that inhibit adherence to 4-vla mediated leukocytes
WO2010000372A3 (en) New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
WO2008060364A3 (en) Humani zed antibody against amyloid beta
EA201290952A1 (ru) Химические соединения
TW200512195A (en) Benzamide 2-hydroxy-3-diaminoalkanes
IL190835A0 (en) Sulfonamide derivatives, their preparation and use
WO2009028457A1 (ja) 非アルコール性脂肪肝炎治療薬
ZA200705018B (en) Malonamide derivatives as inhibitors of gamma-secretase for the treatment of Alzheimer's disease
EP2744802A1 (en) Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi
WO2007067979A3 (en) Targeting vector-phospholipid conjugates
WO2007033080A3 (en) Alzheimer's disease imaging agents
WO2011056477A3 (en) Methods for treating inflammation and oxidative stress related diseases
WO2009076388A3 (en) Targeting vector-phospholipid conjugates
WO2005111020A3 (en) Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4
ZA200803016B (en) Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
EA201390615A1 (ru) Производные дитерпеноидов, обладающие биологическими свойствами
TW200631949A (en) Substituted carboxylic acids
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
WO2007034329A3 (en) Compounds and methods for treatment of amyloid-beta-peptide related disorders
ZA200704921B (en) Sulfonyl amino cyclic derivatives and use thereof

Legal Events

Date Code Title Description
FG Grant or registration